Skip to main content

OpGen Raises $2.1M in Bridge Financing

Premium

OpGen has raised $2.1 million in a securities offering, the company disclosed in a filing with the US Securities and Exchange Commission last week.

The funding round, which had 27 participants, is a bridge financing that will be used to commercialize the Argus Optical Mapping System, the Gaithersburg, Md.-based company told In Sequence's sister publication GenomeWeb Daily News this week. According to the filing, the total size of the round is $2.3 million.

A couple of months ago, the company increased the amount of mapping data the Argus system can produce to 2.5 gigabases per day, making it more useful for the de novo assembly of large genomes. It is also working on a whole-chromosome de novo assembly application to screen for structural variations (IS 10/18/2011).

In a number of demonstration projects, the company has shown that its technology is useful to compare the genomes of different microbial strains, to assist and verify the assembly of microbes, and to help with the assemblies of human, plant, and animal genomes (IS 7/5/2011).

A year ago, OpGen raised $17 million in a Series B financing round, and added another $3 million as part of the same round earlier this year.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.